CoinShares替代币主动型ETF DIME 深 沪
已收盘 04-02 16:00:00 美东时间
7.74
-0.320
-3.97%
华盛通- 最 高7.775
- 今 开7.675
- 成交量 1201股
- 最 低 7.675
- 昨 收 8.06
- 总市值 123.84万
- 52周最高 28.10
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 7.64
- 委 比 42.86%
- 总股本 16.00万
- 历史最高 28.10
- 量 比 1.66
- 振 幅 1.24%
- 历史最低 7.64
- 每 手 1
- 风险率 4.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Nano Dimension Ltd - No Errors Identified In Previously Issued Financial Statements No Restatement Anticipated
BRIEF-Nano Dimension Ltd - No Errors Identified In Previously Issued Financial Statements No Restatement Anticipated March 16 (Reuters) - Nano Dimension Ltd 2N5By.F : NANO DIMENSION LTD - NO ERRORS IDENTIFIED IN PREVIOUSLY ISSUED FINANCIAL STATEMENTS; NO RESTATEMENT ANTICIPATED NANO DIMENSION LTD: 2
03-16 20:14
BRIEF-Dime Announces Elevation Of Jeffrey Barber To Head Of Middle Market C&I Lending, Long Island
BRIEF-Dime Announces Elevation Of Jeffrey Barber To Head Of Middle Market C&I Lending, Long Island March 2 (Reuters) - Dime Community Bancshares Inc DCOM.O : DIME ANNOUNCES ELEVATION OF JEFFREY BARBER TO HEAD OF MIDDLE MARKET C&I LENDING, LONG ISLAND Source text: ID:nGNX9NhKql Further company covera
03-02 21:09
BRIEF-Nano Dimension Adopts Limited Duration Shareholder Rights Agreement
BRIEF-Nano Dimension Adopts Limited Duration Shareholder Rights Agreement Feb 2 (Reuters) - Nano Dimension Ltd 2N5By.F : NANO DIMENSION ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS AGREEMENT Source text: ID:nGNX1dxsdz Further company coverage: [2N5By.F] (( Reuters.Briefs@thomsonreuters.com ;))
02-03 07:30
BRIEF-Evertec To Acquire Dimensa For R$950 Million
BRIEF-Evertec To Acquire Dimensa For R$950 Million Feb 2 (Reuters) - Evertec Inc EVTC.N : EVERTEC TO ACQUIRE DIMENSA FOR R$950 MILLION Source text: ID:nBwknrLGa Further company coverage: EVTC.N (( Reuters.Briefs@thomsonreuters.com ;))
02-03 05:35
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia
Arrowhead Pharmaceuticals Launches Phase 1/2a Trial of Dual-Target RNAi Therapy for Mixed Hyperlipidemia Arrowhead Pharmaceuticals Inc. has announced the initiation of a Phase 1/2a clinical trial for ARO-DIMER-PA, an investigational RNA interference (RNAi) therapeutic being developed for the treatme
01-28 01:02
BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug
BUZZ-Arrowhead rises as it begins trial of high-cholesterol disorder drug ** Shares of Arrowhead Pharmaceuticals rise 2% to $67.95 ** California-based drugmaker says it has begun testing its experimental drug ARO-DIMER-PA for mixed hyperlipidemia, a disorder marked by high levels of cholesterol and
01-27 23:12
BRIEF-Nano Dimension Announces Fourth Quarter 2025 Revenue Exceeding Guidance And Provides Business Updates
BRIEF-Nano Dimension Announces Fourth Quarter 2025 Revenue Exceeding Guidance And Provides Business Updates Jan 21 (Reuters) - Nano Dimension Ltd 2N5By.F : NANO DIMENSION ANNOUNCES FOURTH QUARTER 2025 REVENUE EXCEEDING GUIDANCE AND PROVIDES BUSINESS UPDATES NANO DIMENSION LTD - EXPECTS Q4 2025 REVEN
01-21 21:34
BRIEF-Schneider Electric Sees 'Very Good' Data Centre Demand Outside North America - CEO
Dec 11 (Reuters) - Schneider Electric SE SCHN.PA: CEO BLUM SAYS HE SEES VERY GOOD DATA CENTRE DEMAND OUTSIDE NORTH AMERICA - MEDIA CALL CEO: DEMAND NOT YET SAME MAGNITUDE AS IN US, BUT VERY ROBUST GRO...
2025-12-11 15:55
Arrowhead Pharmaceuticals Unveils Pipeline Progress and First Commercial Launch in Investor Presentation
Arrowhead Pharmaceuticals Inc. has released a corporate presentation highlighting its recent achievements and future plans. The company reported its first commercial launch in 2025 with REDEMPLO® (plo...
2025-12-08 10:05
BRIEF-Tonix, Mass General Partner on Phase 2 Trial of TNX-1500 to Prevent Kidney Transplant Organ Rejection
Nov 4 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL TO ADVANCE PHASE 2 CLINICAL TRIAL OF DIMERIC FC-MODIFIED ...
2025-11-04 20:31
